Loading News...
Back to Dashboard

Vertex Pharmaceuticals Incorpor (VRTX)

Real-time intraday values

Market Overview

From:
To:
VRTX Intraday
No data available
SymbolVRTX
IPO DateJul 24, 1991
CEODr. Jeffrey Marc Leiden M.D., Ph.D.
Full Time Employees6.4k
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNasdaqGS
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Performance
PeriodReturn %Value Change
1 Day
-1.11%
-5.76 US$
5 Days
-4.40%
-23.70 US$
1 Month
-1.84%
-9.63 US$
6 Months
+18.50%
+80.38 US$

Analyzing Market with AI

Evaluating the last 30 days of history and fundamental metrics of VRTX...

Key Statistics
Market Cap
130.58B
P/E Ratio
33.14
Div Yield
0.00%
52W High
$568.67
52W Low
$412.27

Analyst Consensus

ConsensusBuy
Bullish2681.3%
Neutral515.6%
Bearish13.1%

52W Analyst Price Targets

Min Target
$350.00
Max Target
$725.00
Current$514.89
Avg Target$595.36

Analyst Recommendations

Target Price:$595.36($350.00 - $725.00)
FirmRatingTarget PriceUpside PotentialDate
BarclaysOverweight$626.00+21.58%11/4/2026
JP MorganOverweight$570.00+10.70%11/3/2026
Goldman SachsBuy$725.00+40.81%11/3/2026
Morgan StanleyOverweight$660.00+28.18%11/3/2026
ScotiabankSector Outperform$660.00+28.18%11/3/2026
UBSBuy$640.00+24.30%11/3/2026
TD CowenBuy$575.00+11.67%11/3/2026
Wells FargoOverweight$650.00+26.24%11/3/2026
RBC CapitalOutperform$600.00+16.53%11/3/2026
StifelHold$563.00+9.34%11/3/2026

Looking for more stocks? Explore them in the screener

Community Thoughts

Share your analysis and sentiment on VRTX

Join the community to share your analysis